9th July 2020
Pessac (France) – July 2nd, 2020 – inHEART, providing a cloud-based medical image analysis solution for cardiac interventions on patients with arrhythmias, has raised 3.7m€ from Elaia, an EIT Health Investor Network member, and Aquitaine Science Transfert. These funds will be used to accelerate commercial development in Europe, access the US market, and advance its technology leadership with continued development of artificial intelligence and numerical simulations of cardiac electrical activity.
“We are very happy to have Elaia joining inHEART in this adventure not only for its financial support but also for the dynamism and the expertise of its team in developing startups in healthcare. Elaia and inHEART share the same ambition to create a major player in cardiac electrophysiology, a 5B€ market that includes healthcare giants such as Johnson & Johnson, Abbott, Boston Scientific or Medtronic.”, said Jean-Marc Peyrat, CEO and co-founder of inHEART.
Cardiac arrhythmias, a public health issue without miracle solution
Heart rhythm disorders, notably as the cause of sudden cardiac death, is a major cause of morbidity in the world. Current treatment solutions proposed for patients with arrhythmias are not optimal whether considering drugs, implantable devices or even catheter ablation procedures. Particularly for ventricular arrhythmias, these procedures are lengthy, complex, and expensive. Moreover, 40% of patients come back for a repeat procedure due to a recurrence of arrhythmia.
More timely and effective procedures
inHEART provides a cloud-based software solution that transforms preoperative medical images into a 3D digital twin of the patient’s heart. This digital twin enables the cardiologist to better plan the procedure and also to assist in navigating instruments in the patient’s heart. Thereby, we aim at reducing by half procedure duration and failure rates.
An efficient and addictive technology with even more exciting perspectives for the future
inHEART technology has already been used on more than 2 000 patients in more than 40 centers around the world and has been included in the latest international expert recommendations.
“I can’t do without it anymore. My procedures are much simpler and faster. My patients directly benefit from this technology and their arrhythmias are less recurrent. Future will be even brighter with artificial intelligence that already allows us to very quickly process patient scans and that will enable tomorrow the prediction of patients at risk and the refinement of therapeutic strategies.”, commented Prof. Pierre Jaïs, cardiologist and co-founder of inHEART.
French academic excellence at the heart of the project
inHEART is a spin-off from IHU Liryc and Inria, two worldwide leading centers respectively in cardiac electrophysiology and computer science. inHEART was founded by a complementary and experienced team of researchers and physicians, including Maxime Sermesant, expert in AI and cardiac modeling, Hubert Cochet, radiologist expert in cardiac imaging, and Pierre Jaïs, cardiologist who is a pioneer and international key opinion leader in cardiac catheter ablation.
“After more than ten years of multidisciplinary collaboration as only a few exist in the world between cardiologists, radiologists, engineers and researchers in computer science, we have a disruptive technology that answers a real clinical need.”, added Prof. Hubert Cochet, radiologist and co-founder of inHEART.
“inHEART is the perfect match between an advanced technology from Inria and IHU Liryc, known as a center of excellence in cardiac electrophysiology, all of it coordinated by experts who we are glad to follow in this beautiful adventure. Their computational solution to model the heart in 3D revolutionizes cardiac catheter ablation procedures and is already deployed internationally with excellent clinical feedbacks”, said Samantha Jérusalmy, partner at Elaia.
inHEART, an EIT Health Investor Network supported company is a spin-off from IHU Liryc (www.ihu-liryc.fr) and Inria (www.inria.fr), two top-tier research centers respectively in cardiac electrophysiology and computer science, that develops software solutions for medical image processing and cardiac modeling in heart rhythm disorders. inHEART vision is to make the bridge between radiology and cardiology to become a worldwide leader in image-guided diagnosis, therapy planning and navigation software solutions for heart rhythm disorders.
Elaia is a European top-tier VC firm with a strong tech DNA. We back tech disruptors with global ambition from early stage to growth development. For the past 17 years, our commitment has been to deliver high performance with values. We are proud to have been an active partner in over 70 startups including success stories such as Criteo (Nasdaq), Orchestra Networks (acquired by Tibco), Sigfox, Teads (acquired by Altice), Mirakl and Shift Technology.
About the EIT Health and the EIT Health Investor Network
EIT Health is a vast and vibrant community of some of the world’s leading health innovators, backed by the European Union. The EIT Health Investor Network is the first pan-European healthcare network that aims to accelerate early stage equity fundraising.
Contact EIT Health Investor Network: email@example.com
Learn more: https://eithealth.eu/project/investor-network/
Jean-Marc Peyrat: firstname.lastname@example.org
Louisa Mesnard: email@example.com
Four exciting companies receive expert mentoring
EIT Health helps promising firms commercialise
Supported start-up launches AI platform with Roche
Helping cancer patients with AI
EIT Health supported start-up Unhindr awarded £500,000
Unhindr has won funding to scale AI prosthetic device